SpotitEarly Announces an At-Home Cancer Screening Approach

SpotitEarly, an Israeli startup, is developing an AI‑enabled cancer screening that pairs trained dogs with a lab workflow built around breath samples. In a double‑blind study of 1,386 people, researchers reported 93.9% sensitivity and 94.3% specificity in detecting breast, lung, colorectal, and prostate cancers, with 94.8% sensitivity for early‑stage disease.

In the peer‑reviewed study, SpotitEarly trained six Labrador retrievers to analyse breath samples, achieving ~94% accuracy. Today, the company says it employs 18 trained beagles alongside an AI system that monitors the dogs’ physiological and behavioral signals.

Today’s workflow is lab‑based with self‑administered mask collection (typically at clinics) and centralized analysis. The company says it is developing an at‑home version of the test, aiming for U.S. commercial availability in 2026 as it expands operations stateside. SpotitEarly has raised about $20.3 million to fund further studies and scale‑up.

Early detection is often key to effective cancer treatment and can improve survival outcomes. Existing multi-cancer early detection (MCED) tests, such as Grail’s Galleri blood test or whole-body MRIs, can be expensive, sometimes costing consumers around £800 or more. SpotitEarly’s approach uses a non-invasive method and aims to offer a cost-conscious alternative.

Combining canine biosensors with AI validation is an unconventional diagnostic path. Trained beagles assess volatile compounds in breath samples while machine learning algorithms monitor the dogs’ physiological responses. This fusion of biological sensing and digital analysis could enable earlier detection, though the accuracy claims remain under active study.

Founded in Israel in 2020, SpotitEarly has assembled experts across health and biotechnology, alongside a former K9 unit commander. The process begins with users collecting a breath sample at home, which is then analysed in a specialised laboratory. Eighteen trained beagles are employed to detect odours, while cameras, microphones, and heart-rate monitors capture the dogs’ reactions to inform the AI system’s baseline.

A double-blind clinical study published in Nature’s Scientific Reports reported 94% accuracy in identifying signals associated with cancer among 1,386 individuals. Focusing on four cancers—breast, colorectal, prostate, and lung—the authors presented results that indicate potential, with clinical relevance and generalisability to be determined by further research.

SpotitEarly’s technology has recently attracted investment. The company raised $20.3 million from backers including Hanaco VC, Menomedin VC, former Timberland CEO Jeff Swartz, and Avishai Abrahami of Wix. It says the funds will support additional clinical studies, with an initial focus on breast cancer detection before considering other cancer types.

Caveats

The approach—combining canine olfaction with AI—is promising but still under evaluation. The high accuracy in the study needs to be confirmed across broader populations, care settings, and longitudinal use, and the product will require regulatory clearance before routine clinical adoption.

Multi-cancer early detection (MCED) tests face a complex regulatory landscape, with many still awaiting FDA approval. SpotitEarly appears to be in a similar position; it points to ongoing and planned studies as a basis for future regulatory engagement, but outcomes remain to be seen. By pursuing a low-cost, non-invasive screening method and citing accuracy from early studies, the company seeks a competitive footing against established diagnostic tools.

Competition in cancer screening is intensifying, with companies such as Grail and Prenuvo active in the market. SpotitEarly’s blend of canine biosensing with AI validation aims to stand apart from traditional blood or imaging tests. The approach targets a cost advantage and leverages reports that dogs can detect odours linked to disease, although comparative performance and durability of results require further study.

At first glance, integrating dogs into a tech-enabled diagnostic workflow may seem unconventional, but the company frames its method as more than a gimmick. It describes a machine learning framework that monitors dogs’ behaviour—considering breathing patterns, heart rate, and subtle gestures—to set a baseline used for detection within its system. The process is presented as extending beyond canine intuition, though the approach remains under evaluation.

The company’s culture mirrors this focus; employees are expected to be “dog people,” with the canine team treated as a core asset. This strategy of combining biological elements with digital analysis underlines a stated commitment to exploring unconventional methods in healthcare.

Looking ahead, SpotitEarly plans to expand in the United States, aiming to distribute its at-home screening kits through a network of physicians by next year. Initial clinical studies will focus on breast cancer detection before extending the test to include colorectal, prostate, and lung cancers. This phased approach is intended to refine the technology; any reputation for reliability will depend on future results.

Over the coming months, the company aims to deepen its algorithmic analysis as it integrates additional physiological data from its canine team. As biotechnology and AI converge, it will be important to see how regulators and the healthcare industry assess these screening methods. For additional insights and updates on similar innovations, be sure to visit the [Neural Network News archive](https://finesky.ai/category/neural-network-news/